Dose-Response Curves: What "More Isn't Better" Means for Hair Drugs
Affiliate disclosure: This page contains sponsored links. We earn commissions at no extra cost to you. Clinical content is editorially independent.
Every approved hair loss drug has a dose at which incremental benefit plateaus. Exceeding that dose adds side effects without adding efficacy. The evidence is specific and the implications are practical.
Pharmacological dose-response relationships define the dose at which a drug's target effect is maximised and beyond which additional dose adds exposure without proportional benefit. For AGA drugs, these relationships are well-characterised and clinically important.
Finasteride: the 1mg optimum
Finasteride was developed as a 5mg dose for benign prostatic hyperplasia (BPH). When studied for AGA, the dose-response relationship for scalp DHT suppression was established across doses from 0.01mg to 5mg. At 1mg, scalp DHT suppression reached approximately 60–70% — near the plateau of the dose-response curve. Increasing to 5mg produced only marginally more suppression (approximately 70–75%) while delivering five times the systemic exposure.
The AGA pivotal trials used 1mg — the dose at which DHT suppression was clinically adequate and systemic drug exposure was minimised. There is no clinical evidence that 5mg finasteride produces meaningfully better hair outcomes in AGA than 1mg.
Minoxidil: the 5% ceiling
The dose-response for topical minoxidil was established in comparisons of 2% and 5% formulations. The 5% concentration consistently outperformed 2% in hair count and density. Concentrations above 5% have not been systematically studied for hair efficacy; the expectation from the pharmacology is that local SULT1A1 saturation and systemic absorption increase without proportional follicle benefit.
Dutasteride: 90-plus percent DHT suppression
Dutasteride inhibits both 5-AR type 1 and type 2, producing deeper DHT suppression than finasteride's type 2 selective inhibition. At 0.5mg, serum DHT is suppressed by approximately 90–95%. There is limited evidence that the dose range below 0.5mg (0.1–0.25mg) shows a meaningful step-up in hair efficacy in direct comparisons; the standard 0.5mg dose in AGA use is near the top of the dose-response plateau.
The practical implication across all three drugs: the reference doses are not conservative choices — they are the evidence-based optimal doses. Prescribers and patients who increase doses above these levels are adding systemic exposure without established additional benefit, a trade-off that the pharmacology does not support.
Clinical Q&A
Is 5mg finasteride better than 1mg for hair loss?
No. The 1mg dose was selected for AGA specifically because the dose-response curve for scalp DHT reduction flattens at approximately 1mg. The 5mg dose produces marginally more DHT suppression (approximately 70% vs 65% scalp DHT reduction) at substantially more systemic exposure, with higher side effect risk. The 1mg dose provides near-maximal hair-relevant DHT suppression.
Is more minoxidil better?
Not above the reference dose. 1mL of 5% solution delivers the dose at which follicle response is maximised. Studies comparing 2% and 5% showed meaningful additional benefit at 5% over 2%; studies examining supraoptimal doses do not show additional benefit and show increased systemic absorption.
Does a higher dutasteride dose work better?
Dutasteride 0.5mg suppresses serum DHT by approximately 90–95%. There is no established dose above 0.5mg for AGA use and the dose-response curve for DHT suppression is effectively maximal at 0.5mg. Off-label higher doses are sometimes used, without established additional hair benefit and with more systemic androgenic suppression.
References & further reading
- Clark RV, et al. Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor. Journal of Clinical Endocrinology and Metabolism, 2004.
- Olsen EA, et al. The importance of dual 5alpha-reductase inhibition in the treatment of male pattern hair loss: results of a randomized placebo-controlled study of dutasteride versus finasteride. Journal of the American Academy of Dermatology, 2006.
Get a clinical evaluation
Care Bare Rx
Online consultation with licensed prescribers for hair loss evaluation. Compounded finasteride, minoxidil, and combination formulas prescribed and shipped after a clinical intake review.
Start Your Care Bare Rx Intake Paid linkSesame Care
Direct-booking platform for licensed physician consultations. FDA-approved brand-name and generic hair loss prescriptions at transparent prices, no insurance or membership required.
Browse Sesame Care Providers Paid linkCompounded medications: These preparations are made by a pharmacy for an individual patient and are not FDA-approved for safety, effectiveness, or manufacturing quality. Discuss trade-offs with a licensed prescriber.
Affiliate Disclosure: This site earns commissions on referrals at no extra cost to you. Clinical content is independent.
Medical disclaimer: This article is educational and does not constitute clinical advice, diagnosis, or treatment recommendations. Consult a licensed physician or dermatologist before starting, stopping, or changing any medication or treatment for hair loss.